Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...

On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA ...

Ocugen released the data as part of its recent Clinical Showcase presentation, which is also posted on its website, according to a statement.

On Tuesday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.02 or -2.67% from the prior close of $0.75. The stock opened at $0.75 and touched a low of ...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...

Ocugen says that OCU400 differs from highly-specific ... At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s head of ...